Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,007 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy Participants, Upper Gastrointestinal Discomfort
Interventions
Limosilactobacillus reuteri DSM 17648, Placebo
Dietary Supplement
Lead sponsor
Novozymes A/S
Industry
Eligibility
30 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Obesity, Healthy Volunteers
Interventions
S309309, Itraconazole
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3375880 in Healthy Participants

NCT03343587
Conditions
Healthy
Interventions
LY3375880 IV, LY3375880 SC, Placebo IV, Placebo SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Conditions
Chronic Hepatitis Delta
Interventions
GS-4321, GS-4321 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
5
States / cities
Anaheim, California • La Jolla, California • Louisville, Kentucky + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

NCT04756531
Conditions
Healthy Participants
Interventions
PF-07321332 Dose 1, PF-07321332 Dose 2, PF-07321332 Dose 3, PF-07321332 Dose 4, PF-07321332 Dose 5, PF-07321332 Dose 4 or Placebo (Fed)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Completed No phase listed Observational Accepts healthy volunteers

Brain Networks Responsible for Self-Agency

NCT00246831
Conditions
Brain
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Nitrous Oxide: A Dose-Response Analysis - 5

NCT00000253
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
10% N2O, 20% N2O, 30% N2O, 40% N2O
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 37 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 1996
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Healthy Participants
Interventions
CK-4021586, Placebo for CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Hepatitis C
Interventions
GSK2336805 10mg, GSK2336805 30mg, GSK2236805 100mg, GSK2236805 200mg, GSK2236805 10mg, GSK2236805 dose to be determined up to 100mg, GSK2236805 5mg, GSK2236805 30mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Chula Vista, California • Lenexa, Kansas • Willingboro, New Jersey
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of PH-797804 on QTc Interval

NCT01862887
Conditions
Healthy
Interventions
PH-797804, Moxifloxacin, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Healthy Volunteer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05136404
Conditions
Healthy
Interventions
Selpercatinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Healthy
Interventions
IW-6118, Matching Placebo, Naproxen Sodium
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Bioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K, Food Effect of ASP015K
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

NCT02389881
Conditions
Healthy Volunteers
Interventions
TAK-058, TAK-058 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austsitn, Texas
Conditions
No Disease or Condition is Being Directly Studied, The Focus of the Study in Healthy Volunteers
Interventions
Osteopathic manipulation, Sham
Other
Lead sponsor
Lake Erie College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Erie, Pennsylvania
Conditions
Parkinson Disease
Interventions
LY4006896, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
11
States / cities
Los Alamitos, California • Maitland, Florida • Naples, Florida + 7 more
Conditions
Drug Interactions
Interventions
Rosuvastatin, Rosuvastatin + BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety of PAZ-417 in Healthy Elderly Adults

NCT00663065
Conditions
Healthy
Interventions
PAZ-417
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Atopic Dermatitis
Interventions
BBT001, Placebo
Drug
Lead sponsor
Bambusa Therapeutics
Industry
Eligibility
18 Years to 72 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Irvine, California • New York, New York • The Bronx, New York
Conditions
Healthy
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Healthy
Interventions
Olinciguat, Itraconazole
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-05175157 In Healthy Volunteers

NCT01274663
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
South Miami, Florida